Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Darzalex
Pharma
J&J counters Sanofi's Sarclisa nod with Darzalex data drop
J&J is hitting back after Sanofi's first-line multiple myeloma nod last week with a tranche of positive data on a new Darzalex combo regimen.
Fraiser Kansteiner
Sep 27, 2024 3:59pm
Sanofi moves on J&J's Darzalex in first-line myeloma with FDA nod
Sep 20, 2024 4:06pm
With FDA nod, J&J touts new 'foundational' multiple myeloma combo
Jul 31, 2024 10:39am
J&J accounts for Medicare price talks in 2030 growth projections
Jul 17, 2024 11:02am
Analysts predict myeloma market will hit $33B by 2030
Jun 5, 2024 9:40am
J&J reports $133M in sales for new multiple myeloma med Tecvayli
Apr 16, 2024 11:28am
